Hyderabad, undefined

Snehalatha Movva

This inventor holds 1 USPTO granted patent and 4 published patent applications. Top assignee: Dr. Reddy's Laboratories, Incorporated. Active years: 2017.

USPTO Granted Patents = 1 

Average Co-Inventor Count = 13.0

ph-index = 1


Company Filing History:


Years Active: 2017

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Snehalatha Movva: Innovator in Pharmaceutical Science

Introduction

Snehalatha Movva is a prominent inventor based in Hyderabad, India. She has made significant contributions to the field of pharmaceutical science, particularly in the development of innovative drug formulations. Her work has garnered attention for its potential impact on medication efficacy and patient outcomes.

Latest Patents

Snehalatha Movva holds a patent for "Amorphous mirabegron and processes for crystal forms of mirabegron." This invention relates to the amorphous form of mirabegron, an innovative solid dispersion of the drug, and the processes for its preparation. The patent also covers the preparation of α form crystal and β form crystal of mirabegron, along with the pharmaceutical compositions derived from these forms. She has 1 patent to her name.

Career Highlights

Snehalatha is currently employed at Dr. Reddy's Laboratories, Incorporated, where she continues to advance her research and development efforts. Her work at this esteemed organization has positioned her as a key player in the pharmaceutical industry.

Collaborations

Throughout her career, Snehalatha has collaborated with notable colleagues, including Vishweshwar Peddy and Rajesham Boge. These partnerships have facilitated the exchange of ideas and fostered innovation in their respective projects.

Conclusion

Snehalatha Movva's contributions to pharmaceutical science exemplify the importance of innovation in drug development. Her work not only enhances the understanding of mirabegron but also paves the way for future advancements in medication formulation.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…